Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine Humira. The drugmaker has rebounded quite nicely since. AbbVie returned to top-line...
These three companies all have one thing in common: they are all on sale.
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...
AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily...
The drugmaker has convincingly laid to rest the biggest threat to its top line.
These companies have solid businesses and excellent dividend growth track records.
As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.
Most U.S. stocks rose on Wall Street, but drops for Nvidia and some other heavyweight Big Tech companies kept indexes in check
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. Stocks on Monday...
A splashy recent acquisition by the company might not be panning out.